Skip to main content

Evans John M.'s Form 4 filing

Beam Therapeutics Inc. (BEAM) · filed Oct 8, 2021

Accession no.
0000899243-21-039697
Filed
Oct 8, 2021
Trade date
Oct 6, 2021
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 9 non-derivative transactions and 1 derivative transaction. Open-market sales total $4.00M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Evans John M.CIK 0001786304Director, Officer (CEO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Oct 6, 2021Common StockMOption exerciseAcquired+27,700$1.03+$28,5311,061,225Direct
Oct 6, 2021Common StockSSaleDisposed−3,149$82.72F3−$260,485.281,058,076Direct
Oct 6, 2021Common StockSSaleDisposed−13,406$83.47F4−$1,118,998.821,044,670Direct
Oct 6, 2021Common StockSSaleDisposed−10,444$84.45F5−$881,995.81,034,226Direct
Oct 6, 2021Common StockSSaleDisposed−701$85.19F6−$59,718.191,033,525Direct
Oct 6, 2021Common StockSSaleDisposed−2,171$82.71F7−$179,563.41200,829Indirect
Oct 6, 2021Common StockSSaleDisposed−9,863$83.49F8−$823,461.87190,966Indirect
Oct 6, 2021Common StockSSaleDisposed−7,566$84.45F9−$638,948.7183,400Indirect
Oct 6, 2021Common StockSSaleDisposed−400$85.24F10−$34,096183,000Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Oct 6, 2021Common StockMOption exerciseDisposed−27,700$0.00$0331,645Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $82.465 to $82.995, inclusive.

Referenced by the price of 1 transaction in Table I.

F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $83.04 to $83.98, inclusive.

Referenced by the price of 1 transaction in Table I.

F5

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $84.005 to $84.98, inclusive.

Referenced by the price of 1 transaction in Table I.

F6

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $85.03 to $85.32, inclusive.

Referenced by the price of 1 transaction in Table I.

F7

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $82.465 to $82.97, inclusive.

Referenced by the price of 1 transaction in Table I.

F8

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $83.08 to $83.98, inclusive.

Referenced by the price of 1 transaction in Table I.

F9

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $84.07 to $84.98, inclusive.

Referenced by the price of 1 transaction in Table I.

F10

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $85.07 to $85.31, inclusive.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)